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ORIGINAL INVESTIGATION
Midlife development of type 2 diabetes 
and hypertension in women by history 
of hypertensive disorders of pregnancy
Simon Timpka1,2* , Amanda Markovitz1,3, Tommy Schyman4, Ingrid Mogren5, Abigail Fraser6,7,8, 
Paul W. Franks2,3,9 and Janet W. Rich‑Edwards1,3
Abstract 
Background: Women with history of hypertensive disorders of pregnancy (HDP) are at increased risk of early onset 
cardiovascular disease and type 2 diabetes (T2D). We aimed to investigate the extent to which HDP is also associated 
with midlife development of T2D and hypertension above and beyond established risk factors.
Methods: We included parous women who attended population‑based structured clinical visits at age 50 and 
60 years in Sweden 1991–2013 (N = 6587). Women with prior diabetes mellitus, stroke, or ischemic heart disease at 
age 50 years were excluded. Data on reproductive history were collected from registries. To study the association 
between history of HDP and the between‑visits development of T2D, hypertension, and clinical risk factors of cardio‑
metabolic disease (body mass index (BMI), blood pressure, and total cholesterol), we utilized multivariable adjusted 
regression models (logistic, log binomial, and linear regression, respectively). Models included data on outcome risk 
factors at age 50 years, e.g. BMI, 75 g 2 h oral glucose tolerance test result, and mean arterial pressure, respectively.
Results: Between ages 50 and 60 years, 5.8% of initially disease‑free women developed T2D and 31.6% developed 
hypertension. History of HDP was associated with increased risk of developing T2D between age 50 and 60 years 
even when adjusting for risk factors, including BMI, at age 50 years (odds ratio (OR) 1.96, 95% confidence interval (CI) 
1.29–2.98). By contrast, the higher risk of developing hypertension observed in women with history of HDP (relative 
risk (RR) 1.47, 95% CI 1.22–1.78) was attenuated when adjusted for risk factors (RR 1.09, 95% CI 0.94–1.25). Participants 
with a history of HDP had higher mean BMI and blood pressure at age 50 years, with levels roughly corresponding to 
those observed at age 60 years in unaffected women.
Conclusions: Women with history of HDP are not only at higher risk of cardiometabolic disease during their repro‑
ductive years, but HDP is also associated with midlife T2D development above and beyond established risk factors.
Keywords: Hypertensive disorders of pregnancy, Preeclampsia, Gestational hypertension, Epidemiology, Type 2 
diabetes, Hypertension
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Background
Hypertensive disorders of pregnancy (HDP: preeclamp-
sia and gestational hypertension) are potentially life-
threatening obstetric complications that affect 3–10% of 
all pregnancies [1]. Women with a history of HDP also 
develop hypertension at a younger age, [2–4] and are at 
twice the risk of developing type 2 diabetes (T2D) [5, 6] 
and cardiovascular disease (CVD) post-pregnancy [7–
10]. This has led to calls for HDP history to be used for 
identifying women with an adverse risk factor profile at 
a young age [11, 12]. However, less is known about the 
clinical relevance of information on HDP history for car-
diometabolic disease prevention in middle age, especially 
when concomitantly considered with cardiometabolic 
risk factors.
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In this study we were interested in the association 
between HDP history and the development of T2D and 
hypertension in a cohort of women with clinical visits 
at age 50 and 60  years. To mimic a primary prevention 
setting, we sought to estimate associations indepen-
dently of any cardiometabolic deterioration already clini-
cally apparent at age 50  years, and included predictors 
of later cardiometabolic health in our models. To fur-
ther understand the clinical relevance of the association 
between history of HDP and cardiometabolic risk factors 
[including blood pressure and body mass index (BMI)] 
in midlife, we also investigated these associations at age 
50  years, the respective change in any association by 
age 60  years, and compared the associations with those 
attributable to the 10  years of older age between visits. 
Our primary hypothesis was that in women initially free 
of severe cardiovascular disease, history of HDP is posi-
tively associated with developing T2D and hypertension 
between age 50 and 60  years also when accounting for 
conventional predictors of cardiometabolic deterioration 
measurable at age 50 years.
Methods
In this prospective cohort study, we utilized a com-
bination of clinical data, collected in a standardized 
population-based setting in northern Sweden, and com-
prehensive registry resources on reproductive history 
including pregnancy complications. Data on hospitaliza-
tions and cause of death were collected from the Swedish 
in-patient and Cause of Death Registry, respectively. Data 
on place of residence and educational level were collected 
from Statistics Sweden (Örebro, Sweden).
Study sample identification
We included parous women who attended population-
based structured clinical visits in primary care (The 
Västerbotten Intervention Program) at age 50, and again 
10  years later, both visits occurring between 1991 and 
2013 in northern Sweden (Fig.  1). Of 11,244 potentially 
eligible parous women, we included 8720 women with 
full reproductive history. This was defined as living in 
the geographical area covered by the regional pregnancy 
register in 1968, when data on place of residence for all 
participants were available. Women with known diabetes 
mellitus during pregnancy were excluded as these women 
are already known to have a very high risk of T2D and 
because we did not have data on pre-pregnancy diabetes 
status. The identification of the study sample is shown in 
Fig.  1. We excluded women with severe cardiovascular 
disease before the first visit at age 50 years (stroke, tran-
sient ischemic attack, myocardial infarction, or angina) 
according to in-patient ICD codes (version 9 or 10) or 
self-report, including anti-angina medication. As there 
was a small proportion of missing data in our final sam-
ple (< 5% missing any variable), we performed complete 
case analyses for each outcome.
Data on reproductive history
Data on reproductive history, including HDP (hyperten-
sion in pregnancy, preeclampsia, and eclampsia), were 
collected from regional to national delivery registries. 
In short, we utilized a local birth registry for the period 
1955–1972 [13] (see Additional file  1) and the national 
Swedish Medical Birth Registry for the period from 1973 
onwards. We utilized ICD codes to identify women with 
a reported diagnosis of HDP or diabetes mellitus during 
pregnancy (see Additional file 1 for ICD codes).
Cardiometabolic measurements at age 50 years visit 
and at the 10‑year follow‑up
All women aged 50 and 60 years living in the county of 
Västerbotten in northern Sweden have since 1991 been 
invited to undergo standardized health assessments, 
focused on cardiometabolic health prevention, at their 
primary care centers [14, 15]. Study visits are conducted 
by a nurse and, for participants who are not already diag-
nosed with diabetes mellitus, typically include a 75  g 
2 h oral glucose tolerance test (OGTT). For the purpose 
of this study, diabetes mellitus was defined either as (I) 
self-report of previous diagnosis (II) fasting capillary 
plasma glucose (≥ 7.0 mmol/l) (III) 2 h capillary plasma 
glucose > 12.1 (IV) currently taking anti-diabetic drugs 
or (V) reporting lifestyle treatment for diabetes. Total 
serum cholesterol was analyzed locally at each primary 
health care center using a Reflotron bench analyzer until 
August 2009 and then onwards at the central clinical 
chemistry lab at Umeå University Hospital. From 1991 to 
August 2009, blood pressure was measured with a sphyg-
momanometer with the participants in a horizontal posi-
tion after a five min rest. From September 2009 onwards, 
blood pressure was measured with the participants in a 
seated position. As the large majority of the blood pres-
sure measurements in this study was performed prior to 
2009, we converted all measurements taken with the par-
ticipant in a seated position to horizontal values by using 
age-specific formulae [16]. We defined hypertension 
as either (I) systolic blood pressure (SBP) ≥ 140  mmHg 
(II) diastolic blood pressure (DBP) ≥ 90  mmHg or (III) 
self-report use of anti-hypertensive drugs. Mean arte-
rial pressure was calculated as DBP + [(SBP − DBP)/3]. 
Participant body weight and height were measured by a 
nurse and BMI was calculated as (weight in kg)/(height in 
m)2. Smoking habits, family history of diabetes mellitus, 
and family history of CVD were collected via self-admin-
istered questionnaires.
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As previously recommended, [17] for these analyses we 
added a constant to the clinical measurement to compen-
sate for anti-hypertensive or lipid-lowering medication, 
respectively. When analyzing continuous blood pressure, 
we added a standard 15 mmHg to SBP and 10 mmHg to 
DBP if participants reported anti-hypertensive drug use 
[17]. When analyzing continuous serum cholesterol, we 
added 1.336 mmol/l for participants who reported use of 
lipid lowering drugs [18].
Statistical analyses
In the analyses of binary outcomes, we investigated the 
associations between history of HDP and 10-year risk 
of developing of T2D and hypertension between 50 and 
60  years of age. We utilized logistic regression for T2D 
and, as we anticipated a high prevalence of hyperten-
sion at follow-up, we utilized log binomial regression 
to directly obtain a risk ratio and 95% confidence inter-
val  (CI) for hypertension. In Model I, we included HDP 
history. In Model II, we adjusted for family history of 
CVD and T2D, BMI, smoking, education level, and 
year of birth. In the main model (Model III), we fur-
ther included a measure of already accumulated risk 
of the outcome at age 50  years (capillary glucose at 2  h 
post OGTT for T2D and mean arterial pressure at age 
50 years for the hypertension analyses, respectively).
In the analyses of continuous outcomes, we investi-
gated the association between history of HDP and several 
cardiometabolic risk factors (BMI, SBP, DBP, log total 
serum cholesterol) at ages 50 and 60 years and whether 
these associations changed with age. To do so we used 
linear mixed models with fixed effects for the between-
participant variation. We estimated 95% CIs and calcu-
lated complementary p-values. In Model I, we included 
HDP history, age at clinical visit, and an interaction 
term between the HDP history and age. In Model II, we 
adjusted for family history of CVD and family history 
of diabetes mellitus. In the main model (Model III), we 
further included education level, smoking, year of birth, 
BMI (when BMI was not the dependent variable), as well 
Fig. 1 Identification of study sample. The figure shows the identification of each analytic sample used to examine the associations between history 
of HDP and 10 year risk of T2D and hypertension in women 50 years of age. BMI body mass index, DBP diastolic blood pressure, DM FH diabetes 
mellitus family history, SBP systolic blood pressure, T2D type 2 diabetes
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as interaction terms for age and smoking and age and 
BMI (when BMI was not the dependent variable). Par-
ticipants eligible for these analyses had no missing data at 
either of their visits, resulting in 6504–6582 participants 
contributing data (Fig. 1).
As an additional analysis we wanted to replicate pre-
vious findings on the association between history of 
HDP and post-pregnancy development of T2D and 
hypertension. To do so, we used regression models, as 
described above for T2D and hypertension, but did not 
exclude women based on their cardiometabolic sta-
tus at age 50  years. Instead, we utilized the data from 
the initial age 50  years clinical visit as outcome data. 
In addition to a crude analysis, we analyzed mod-
els adjusted for education level and family history. All 
analyses were performed using SAS 9.4.
Results
Table  1 shows the participant characteristics stratified 
by history of HDP. In total, 285 (4.3%) women had at 
least one pregnancy complicated by HDP and result-
ing in a birth. Whereas women with a history of HDP 
had similar educational level as women not affected, 
they had markedly higher blood pressure at ages 50 
and 60  years. During the 10  years of follow-up from 
age 50 years, 385 (5.8%) participants developed T2D of 
whom 36 women (9.4%) had a history of HDP. Of the 
4958 normotensive participants at age 50 years, includ-
ing 10 participants with missing data and not included 
in the regression model, 1568 (31.6%) had developed 
hypertension 10 years later.
Confirmation of the association between history 
of hypertensive disorders of pregnancy 
and cardiometabolic disease at age 50 years
The analyses focusing on cardiometabolic disease 
development between pregnancy and age 50  years 
included 8601 women in the T2D analysis and 8476 
women in the hypertension analysis. In these analyses, 
history of HDP was associated with an increased odds 
ratio (OR) of T2D in both the crude (OR 3.26, 95% 
CI 2.13–4.99) and adjusted analysis (OR 3.13, 95% CI 
2.04–4.80). Likewise, HDP history in any pregnancy 
was associated with an increased risk of hypertension 
Table 1 Study sample characteristics by history of HDP
Dashes in columns are markers of no missing data in the study sample
BMI body mass index, DBP diastolic blood pressure, MAP mean arterial blood pressure, OGTT oral glucose tolerance test, SBP systolic blood pressure
* Percentage not adding up to 100% due to rounding
No history of HDP HDP history
Missing data, N Missing data, N
N participants (%) 6302 (95.7) – 285 (4.3) –
Age at age 50 visit, years mean ± SD 50.1 ± 0.3 – 50.1 ± 0.3 –
Age at age 60 visit, years mean ± SD 60.0 ± 0.2 – 60.0 ± 0.2 –
Family history of CVD, N (%) 1787 (28.4) – 92 (32.3) –
Family history of diabetes, N (%) 1968 (31.2) – 99 (34.7) –
MAP at 50 years, mmHg mean ± SD 95 ± 13 68 106 ± 14 4
SBP at 50 years, mmHg mean ± SD 127 ± 19 61 141 ± 20 4
SBP at 60 years, mmHg mean ± SD 136 ± 20 5 146 ± 19 –
DBP at 50 years, mmHg mean ± SD 79 ± 11 67 88 ± 13 4
DBP at 60 years, mmHg mean ± SD 82 ± 11 7 87 ± 11 –
BMI at 50 years, kg/m2 mean ± SD 25.3 ± 4.0 – 26.5 ± 4.5 –
BMI at 60 years, kg/m2 mean ± SD 26.4 ± 4.5 5 27.4 ± 4.8 –
2 h glucose post‑OGTT at age 50 years, mmol/l mean ± SD 6.78 ± 1.3 233 6.92 ± 1.4 11
Education level, N (%) – –
 Elementary school or less 1167 (18.5) 56 (19.7)*
 High school 3390 (53.8) 157 (55.1)*
 College/University 1745 (27.7) 72 (25.3)*
Cholesterol age 50 years, mmol/l median (IQR) 5.62 (4.99; 6.35) 59 5.83 (5.10; 6.65) 1
Cholesterol age 60 years, mmol/l median (IQR) 5.95 (5.30; 6.64) 11 6.00 (5.38; 6.76) 1
Smoking age 50 years, N (%) 1449 (23.0) – 54 (19.0) –
Smoking age 60 years, N (%) 911 (14.5) – 32 (11.2) –
Page 5 of 9Timpka et al. Cardiovasc Diabetol  (2018) 17:124 
at age 50  years (relative risk (RR) 2.27, 95% CI 2.06–
2.51 and 2.22, 95% CI 2.01–2.44, respectively).
History of hypertension disorders of pregnancy 
and midlife development of cardiometabolic disease
Table  2 shows history of HDP to be associated with 
incident T2D between age 50 and 60  years, even after 
adjusting for cardiometabolic health, including glucose 
response to OGTT, at age 50  years (OR 1.96, 95% CI 
1.29–2.98). History of HDP was associated with inci-
dent hypertension between age 50 and 60 years (crude 
RR 1.47, 95% CI 1.22–1.78) but this association was 
abrogated in the model that adjusted for blood pressure 
and other risk factors at age 50 years (RR 1.09, 95% CI 
0.94–1.26).
History of hypertensive disorders of pregnancy 
and cardiometabolic risk factor status at age 50 
and 60 years
Table  3 shows history of HDP to be associated with 
approximately one unit higher BMI at both age 50 and 
60 years, as evidenced in the second column and the lack 
of interaction between age and HDP history in the sixth 
column. History of HDP was also associated with higher 
SBP and DBP and this difference at age 50 years (on the 
order of 12  mmHg SBP and 8  mmHg DBP) are greater 
or comparable to the age-related difference (roughly 
10 mmHg SBP and 4 mmHg DBP) between visits at age 
50 and 60  years in all women. However, the absolute 
effect size attributable to history of HDP was roughly 
3  mmHg lower at age 60  years for both DBP and SBP 
compared to age 50 years (p for interaction < 0.05 for all 
BP comparisons). Although history of HDP was associ-
ated with higher total serum cholesterol at both age 50 
and 60 years, these associations were small compared to 
the age-related increase.
Additional analyses
When we compared the characteristics at age 50  years 
for women who did and did not attend the follow-up 
visit, there was no difference in educational level or 
proportion of women with history of HDP (Additional 
file  1: Table  S1). However, women who did not attend 
the age 60 years visit were more likely to be smokers at 
age 50 years and had a tendency of worse mean OGTT 
result or being hypertensive at the initial visit. Women 
(N = 2524) who were excluded due to missing repro-
ductive history had similar prevalence of diabetes at age 
50 years compared to the study sample (Additional file 1: 
Table S2). The excluded women had higher level of edu-
cation and slightly lower blood pressure at age 50 years. 
However, the absolute difference in blood pressure was 
small compared to the estimate associated with having a 
history of HDP in the main sample.
Discussion
We found history of HDP to be positively associated with 
incident T2D in women between age 50 and 60  years 
even after adjustment for clinical risk factors at age 
50 years, including OGTT result. By contrast, for hyper-
tension this association was abrogated when we adjusted 
for risk factors, including MAP. Although the absolute 
difference in blood pressure was smaller by age 60 years, 
women with a history of HDP had higher mean BMI and 
blood pressure at both age 50 and 60 years. Their respec-
tive level at age 50 years roughly corresponded to those 
observed at age 60 years in unaffected women.
Hypertensive disorders of pregnancy as a predictor of T2D
In our main analysis we have included women without 
T2D or CVD at age 50 years, controlled for their risk at 
50 years, and followed them for 10 years. This approach 
is novel in the field and, by and large, it mimics a pri-
mary prevention setting in which women not yet diag-
nosed with severe cardiometabolic disease seek advice 
on prevention and disease risk from their health care 
provider. To replicate the decision process in the pri-
mary care setting, we include known predictors of these 
outcomes likely to be available to the primary care clini-
cian, to investigate the additional value of HDP history 
as a clinical predictor above and beyond what is already 
considered by practitioners. The results suggest that 
Table 2 HDP and  incident type 2 diabetes 
and hypertension between age 50 and 60 years
Model I includes: history of HDP (yes or no)
Model II additionally includes: family history of diabetes mellitus (yes or no), 
family history of cardiovascular disease (yes or no), body mass index at age 
50 years, education level (9 years or less, 10–12 years, > 12 years), smoking status 
at age 50 years (yes or no), and year of birth
Model III additionally includes: capillary glucose at 2 h following 75 g OGTT 
at age 50 years (for T2D) or mean arterial pressure at age 50 years (for 
hypertension)
CI confidence interval, HDP hypertensive disorders of pregnancy, OR odds ratio, 
RR relative risk, T2D type 2 diabetes mellitus, OGTT oral glucose tolerance test
a Modelled with logistic regression
b Modelled with log binomial regression
Model OR of T2D (95% CI)a RR 
of hypertension 
(95% CI)b
Model I 2.35 (1.61; 3.44) 1.47 (1.22; 1.78)
Model ÏI 1.98 (1.33; 2.95) 1.30 (1.10; 1.53)
Model III 1.96 (1.29; 2.98) 1.09 (0.94; 1.25)
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information on history of HDP may be clinically use-
ful for the prediction of midlife T2D development in 
women. The strong link between HDP history and meta-
bolic function is supported by a previous study in which 
post-pregnancy obesity modified the association between 
history of HDP and hypertension [19]. When we inves-
tigated the relative risk of disease by HDP history at age 
50  years, we in this study also confirm previous results 
suggesting women with history of HDP have increased 
risk of T2D and hypertension during the decades fol-
lowing pregnancy [4, 8]. Sattar et al. suggested that preg-
nancy complications constitute potential susceptibility 
to future cardiometabolic disease [12] and our results 
suggest that history of HDP actually has potential as a 
clinical predictor of T2D in middle age. This susceptibil-
ity could potentially be mediated through a more adverse 
vascular, inflammatory and/or insulin resistant [20] pre-
disposition that is tentatively revealed during pregnancy.
Fraser et al. reported that women with either a history 
of preeclampsia or gestational hypertension had worse 
risk factor profile and higher calculated CVD risk at mean 
age 48 years [21]. In several studies, history of HDP has 
also been reported to be associated with increased risk 
of hypertension post-pregnancy [2, 22]. Our results sug-
gest that history of HDP is associated with hypertension 
development midlife, but that this association is largely 
attenuated when blood pressure at the beginning of the 
10-year interval is accounted for. Drost et  al. reported 
on the longitudinal changes of cardiometabolic risk fac-
tors in middle age by HDP history [23]. In their analysis, 
history of HDP was associated with higher blood pres-
sure but compared to this study the effect estimates were 
smaller. However, the prevalence of history of HDP in the 
study was noticeably high at 20%. Our results also sup-
ports that women with history of HDP have higher BMI 
compared to other parous women, [24] but the absolute 
difference did not increase during midlife.
Several studies suggest an association also between 
maternal HDP and worse offspring metabolic health later 
in life [25, 26]. However, the extent to which this associa-
tion can translate into improved prediction in adulthood 
above and beyond established determinants is unknown.
Table 3 The association of HDP history and CVD risk factors at age 50, the change in CVD risk factors from age 50 to age 
60 years, and the interaction between HDP history and age
Model I includes: history of HDP (yes or no), age at visit (50 or 60 years), interaction term between HDP and age at visit
Model II additionally includes: family history of diabetes mellitus (yes/no), family history of cardiovascular disease (yes or no)
Model III additionally adjusts for: smoking (yes or no), interaction term between age and smoking, education level (9 years or less, 10–12 years, > 12 years), year of 
birth, BMI (not in model with BMI as outcome), interaction between age and BMI (not in model with BMI as outcome)
BMI body mass index, CI confidence interval, CVD cardiovascular disease, DBP diastolic blood pressure, HDP hypertensive disorders of pregnancy, OGTT oral glucose 
tolerance test, SBP systolic blood pressure
a For cholesterol the results are presented as difference in percentage as the outcome is log transformed
b The effect estimate of 10 years age increase from age 50 years is shown for comparison with the effect estimate of HDP history at age 50 years
c Column shows the difference in associations with HDP history at age 60 years compared to age 50 years
Age 50, 
no HDP 
history
Mean  differencea 
at age 50 years 
in women with history 
of HDP (95% CI)
p, history of HDP Mean difference, age 
60 vs. 50 years (95% 
CI)b
p, age Interaction, history 
of HDP and age 
60 years (95% CI)c
p, interaction
BMI, kg/m2
 Model I Reference 1.16 (0.66; 1.66) < 0.001 1.12 (1.06; 1.17) < 0.001 − 0.15 (− 0.42; 0.12) 0.27
 Model II Reference 1.13 (0.63; 1.63) < 0.001 1.12 (1.06; 1.17) < 0.001 − 0.15 (− 0.42; 0.12) 0.27
 Model III Reference 1.09 (0.59; 1.59) < 0.001 1.06 (1.00; 1.12) < 0.001 − 0.15 (− 0.42; 0.12) 0.27
SBP, mmHg
 Model I Reference 13.5 (11.2; 15.8) < 0.001 8.28 (7.85; 8.72) < 0.001 −2.84 (− 4.94; − 0.73) 0.01
 Model II Reference 13.3 (11.1; 15.6) < 0.001 8.28 (7.85; 8.72) < 0.001 −2.84 (− 4.94; − 0.73) 0.01
 Model III Reference 11.5 (9.32; 13.7) < 0.001 10.2 (7.44; 12.9) < 0.001 − 2.41 (− 4.49; − 0.33) 0.02
DBP, mmHg
 Model I Reference 8.58 (7.23; 9.93) < 0.001 2.46 (2.20; 2.73) < 0.001 −3.15 (− 4.42; − 1.89) < 0.001
 Model II Reference 8.50 (7.15; 9.85) < 0.001 2.46 (2.20; 2.73) < 0.001 − 3.15 (− 4.42; − 1.89) < 0.001
 Model III Reference 7.55 (6.25; 8.86) < 0.001 4.06 (2.42; 5.71) < 0.001 − 2.91 (− 4.18; − 1.65) < 0.001
Total serum cholesterol, %a
 Model I Reference 3.9 (1.4; 6.4) 0.002 5.1 (4.5; 5.7) < 0.001 − 1.9 (− 4.7; 1.0) 0.20
 Model II Reference 3.8 (1.3; 6.3) 0.003 5.1 (4.5; 5.7) < 0.001 − 1.9 (− 4.7; 1.0) 0.20
 Model III Reference 3.5 (1.0; 6.0) 0.007 16.8 (13.1; 20.5) < 0.001 − 1.5 (− 4.3; 1.4) 0.30
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Limitations
By combining population-based clinically collected data 
with registry resources, we have assembled a large sam-
ple with objectively measured outcome data and com-
plete reproductive history. However, the study also has 
potential limitations. We report a loss to follow-up of 
20% at the age 60 years visit. While there was no differ-
ence in history of HDP status or education level by hav-
ing attended the follow-up visit, the group that did not 
appeared to have a higher proportion of smokers and 
worse OGTT result. Regardless, our main study results 
depend on the assumption that loss of follow-up between 
study visit 1 and 2 does not induce major bias. As we 
mainly had outcome data registered at the follow-up 
visits at age 60 years, we did not utilize a survival model 
but analyzed the outcomes by that time point. We did 
not have full reproductive history on all women attend-
ing the age 50 years visit. As the reproductive data were 
mainly collected from a comprehensive regional register, 
it is likely that women missing reproductive history had 
immigrated to the region during or after their childbear-
ing years. We do not think that it is plausible that the 
presented associations would vary greatly (i.e. presence 
of an interaction) between women who have delivered 
any children outside the counties covered by the register 
compared to those who have not. Still, additional stud-
ies in samples of other populations are needed to confirm 
the novel results we present. Of note is also that GDM 
was yet to be established as a distinct diagnostic entity in 
the 1950–1960s, and we do not have data on pre-preg-
nancy diagnoses. Thus, we cannot separate GDM from 
diabetes mellitus present prior to pregnancy. However, 
women with GDM or diabetes mellitus are excluded from 
the analytical sample in the main analysis. Similarly, we 
are not able to exclude women with hypertension prior to 
pregnancy. The HDP diagnoses are mostly collected from 
a regional register in which the specific accuracy has not 
been evaluated. However, data from Norway suggest 
that diagnoses on HDP set in the 1960s were of reason-
able quality and provided some separation even between 
preeclampsia and gestational hypertension [27].
Clinical relevance and future studies
In contrast to the guidelines concerning GDM, which 
currently recommend regular screening for T2D, [28] 
the guidelines for follow-up after HDP are less specific 
[29]. Our results show that history of HDP is not only 
a post-pregnancy risk factor of T2D, but also a predic-
tor of midlife T2D development even after adjusting 
for post-pregnancy metabolic status. Nonetheless, the 
clinical utility of history of HDP should also be investi-
gated in less ethnically homogenous populations. As the 
awareness of the link between HDP history and later 
cardiometabolic disease is insufficient among physicians 
in the United States, [30, 31] efforts are needed to inform 
clinical practice regardless. By conveying the message of 
the worse cardiometabolic status associated with history 
of HDP through comparisons with age-related decline, 
[32] the communication of guidelines and their penetra-
tion to clinical practice might be facilitated.
Conclusions
In this study we found history of HDP to be associated 
with midlife T2D development in parous women initially 
free of severe cardiometabolic disease, even when adjust-
ing for established predictors of cardiometabolic dete-
rioration. This suggests that history of HDP as a clinical 
predictor of T2D development in middle aged women 
warrants further study. Women affected by HDP also had 
worse cardiovascular risk factor status at age 50  years, 
which roughly corresponded to 10 years of older age. In 
conclusion, our results suggest that information on previ-
ous HDP is not only relevant for the risk of cardiometa-
bolic disease during the decades post-pregnancy, but 
might also be clinically useful to predict middle age T2D 
development above and beyond established risk factors.
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full reproductive history at age 50 years.
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